Search Results

Viscient Bio, Inc. (“Viscient”) today announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells.

Viscient Biosciences announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medical research institute, and Salk Institute, have published the first demonstration of a liver fibrosis phenotype in a 3D human tissue model of MASH demonstrating strong comparability to the native disease by multiple measures.

Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.